KVKaren M. Vuckovic

Karen M. Vuckovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karen M. Vuckovic has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding the Autonomic Nervous System: A How-To Guide for Designing Engaging Pathophysiology and Pharmacology Courses for Nursing Students

    by Anne M. Fink, Sarah R. Martha, Michael W. Calik, Jennifer Maffucci, Sarah M. Fitz, Mark B. Lockwood, Laurie Quinn, Kathryn J. Vanderzwan, Cynthia Fritschi, Julie Schwind, et al.

    Aim. The objective of this article is to describe our innovative competency-based approach to teaching nursing students about the autonomic nervous system (ANS). Background. Nurse educators require resources about pedagogical approaches related to ANS instruction. Design and Methods. We implemented an approach based on Kolbs Experiential Learning Theory, which was piloted in several nursing courses that spanned undergraduate and graduate levels of education. Results. We organized content according to three core ANS concepts: receptors and ligands; neurotransmission; and ANS divisions and reflexes. After students demonstrated mastery of these concepts, we introduced active-learning exercises, such as case studies, interactive games, concept mapping, and simulation-based education. This approach layered clinically-relevant information upon the core concepts. We leveraged student feedback by adding historical, social science, and literary examples into lectures because students reported how this approach made the material engaging. Conclusion. Our approach guides students toward a conceptual understanding of the ANS to support critical thinking and enhance nursing skills, such as interpreting physiologic signals, titrating vasoactive medications, and recognizing ANS disorders.


  • mHealth Technology and CVD Risk Reduction

    by Maan Isabella Cajita, Yaguang Zheng, Jacob Kigo Kariuki, Karen M. Vuckovic, Lora E. Burke

    Purpose of Review To review existing mHealth-based interventions and examine their efficacy in reducing cardiovascular disease (CVD) risk factors. Recent Findings A total of 50 articles are included in this review. The majority of the mHealth interventions targeted a specific CVD risk factor, while 4 addressed 2 or more CVD risk factors. Of the 9 mHealth-supported weight loss intervention trials, 4 resulted in significant weight loss. Four out of 7 RCTs targeting improvement in physical activity reported significant improvement, while 4 of the 8 mHealth-supported smoking cessation intervention trials resulted in smoking abstinence. Of the 10 mHealth-based diabetes intervention trials, 5 reported significant reductions in HbA1c; however, only 3 out of the 9 antihypertension interventions resulted in significant reductions in blood pressure. Summary There is a growing body of literature focused on mHealth interventions that address CVD risk factors. Despite the immense potential of mHealth interventions, evidence of their efficacy in mitigating cardiovascular risk is heterogeneous.


  • 20 Things You Didn’t Know About β-Blockers

    by Karen M. PhD Vuckovic, Adam PharmD Bursua

  • Open Access

    Estimated Glomerular Filtration Rate and 6-Minute Walk Distance in African Americans with Mild to Moderate Heart Failure

    by Karen M. Vuckovic, Houry Puzantian

    Background/Aims: The 6-minute walk test is a measure of functional capacity in patients with heart failure (HF) or chronic kidney disease (CKD). The association between estimated glomerular filtration rate (eGFR) and 6-minute walk distance (6MWD) has not been investigated in African-Americans (AA), despite them having a higher incidence of CKD and chronic HF. Thus, our aim was to determine if eGFR was an independent predictor of 6MWD in AA >50 years of age with HF. Methods: In this cross-sectional study, we examined the relationship between eGFR and 6MWD in 45 AA patients with HF from an urban outpatient HF clinic, using logistic regression with bootstrapping. Results: The sample consisted of 53% females; mean age = 64.8 ± 9 years, mean eGFR = 61.6 ± 20 mL/min/1.73 m2, and mean 6MWD = 222 ± 78 m. A decrease in eGFR by 10 mL/min/1.73 m2 was associated with 46% higher odds (p = 0.02) of a 6MWD ≤200 m in an unadjusted model and 39-41% higher odds (p = 0.03) of a 6MWD ≤200 m in adjusted models. Conclusion: A decrease in eGFR significantly predicted a shorter 6MWD in AA patients with HF. Therefore, a reduction in eGFR may be used as an early marker to identify and manage declining functional capacity in these patients.


  • Measurement of Dyspnea in Ambulatory African Americans With Heart Failure and a Preserved or Reduced Ejection Fraction

    by Karen M. Vuckovic, Holli A. DeVon, Mariann R. Piano

    Dyspnea is a burdensome and disabling heart failure (HF) symptom. Few studies examining dyspnea in HF have included African Americans (AAs), despite their developing HF at a younger age and having the highest mortality rates.The purpose of this cross-sectional study was to examine dyspnea in AA patients with HF and a preserved ejection fraction (HFpEF) compared with those with a reduced ejection fraction (HFrEF), before and after the 6-minute walk test (6MWT).A convenience sample of ambulatory AA patients (HFrEF, n = 26; HFpEF, n = 19) 50 years or older was recruited from an urban HF clinic. The Borg Scale and a visual analog scale (VAS) were used to measure dyspnea intensity before and after the 6MWT. Activity limitations related to dyspnea were described using the modified Medical Research Council Dyspnea Scale. Group comparisons were analyzed using repeated-measures analysis of variance and χ tests. Convergent validity was determined between the Borg and VAS using Bland-Altman plots.No significant differences were found in age, gender, and comorbidities between HF groups. Most HFpEF patients reported dyspnea at baseline (Borg, 63%; VAS, 73%) and after the 6MWT (Borg, 78%; VAS, 79%). In the HFrEF group, the prevalence of baseline dyspnea was greater when measured with the VAS (Borg, 34%; VAS, 80%) but was similar between instruments after the 6MWT (Borg, 64%; VAS, 77%). Both groups reported a similar change in dyspnea intensity during and after the 6MWT. The Bland-Altman plots indicated moderate agreement at each time point. Most patients described walking hurriedly or uphill as dyspnea-provoking on the Modified Respiratory Council Dyspnea Scale.The prevalence of dyspnea at baseline and after the 6MWT was high for both groups, but intensity varied with the dyspnea instrument used.


  • The 6-Min Walk Test

    by Karen M. Vuckovic, Anne M. Fink

    The 6-min walk (6MW) is a self-paced test for measuring functional capacity. Lower 6MW distances have been associated with adverse outcomes in patients with heart failure. The purpose of this article is to describe the history of the 6MW test and to evaluate its reliability, validity, and predictive value as well as the responsiveness of the test to therapies. In the literature we reviewed, reliability was affected by several factors including learning effects and protocol deviations. The 6MW distance was moderately correlated with peak oxygen consumption derived from cardiopulmonary exercise stress testing. In some studies the 6MW distance was predictive of hospitalization and mortality. In pharmacological and cardiac resynchronization trials the 6MW distance did not consistently detect clinical improvements. Despite limitations, the 6MW test is a viable alternative to stress testing for objectively evaluating functional capacity in some settings. We provide recommendations for using the 6MW test in future studies.